Drug Approval | May 07, 2026
Venus Remedies gets marketing authorization for Ceftriaxone in Argentina
Approval strengthens the company’s growing international anti-infective portfolio
Approval strengthens the company’s growing international anti-infective portfolio
The 40-second film brings children to the forefront of the narrative
Supported by Plan International, the partnership will help treat over 1,000 children annually
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
This is an exciting and meaningful milestone for GRIN Therapeutics
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Subscribe To Our Newsletter & Stay Updated
